A Pill That’s Gaining Traction Fast
When Eli Lilly’s oral GLP‑1 drug Foundayo hit U.S. shelves in April, the buzz was louder than a launch party. In a recent CNBC interview, CEO Dave Ricks revealed that roughly one‑third of every new GLP‑1 patient is now choosing the pill over injectable rivals. That isn’t just a happy accident—it’s the result of a deliberate push to capture a market that Novo Nordisk has traditionally dominated.
Ricks said Lilly’s share of the oral segment is climbing “week over week,” and the company feels confident about its long‑term foothold. The momentum is not only domestic; Lilly plans to roll Foundayo out to additional international markets in the coming months, widening the drug’s reach beyond American pharmacies.
Manufacturing Muscle: The Houston Megafacility
Behind the sales surge is a $6.5 billion manufacturing campus that broke ground on a 240‑acre parcel in Houston’s Generation Park. Expected to be up and running by 2030, the plant will be a one‑stop shop for Foundayo’s active ingredients and a host of Lilly’s other small‑molecule therapies, spanning cardiometabolic health, oncology, immunology, and neuroscience.
This isn’t Lilly’s first foray into reshoring production. In February 2025 the company pledged an extra $27 billion to build four new facilities, signaling a broader strategy to bring critical drug manufacturing back to U.S. soil.
- Projected operational date: 2030
- Investment total: $6.5 billion for the Houston site
- Scope: Foundayo plus active ingredients for multiple therapeutic areas
What This Means for Investors and Patients
While Novo’s shares slipped after investors voiced doubts about its ability to keep pace with Lilly, the market data tells another story. Lilly claimed a 61 % share of the overall GLP‑1 market in Q2, a figure that underscores the company’s rapid ascension.
For investors, the combination of a high‑growth product and a massive, vertically integrated manufacturing hub reduces supply‑chain risk—a key concern in today’s biotech landscape. For patients, a convenient oral option could broaden access, especially for those hesitant about injections.
Ultimately, Lilly’s aggressive expansion is a bet that the obesity and diabetes markets will keep expanding, and that an oral formulation will become the preferred entry point for many new users.
Only time will tell if Foundayo can sustain its early success, but the signs point to a new era where a pill might finally rival the injection‑driven dominance of the GLP‑1 class.
Photo by Alex Luna on Pexels
